Shandong Luoxin Pharmaceutical
Linyi, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An integrated pharma company with a commercial base in generics, developing innovative small molecule drugs for cancer and heart disease.
OncologyCardiovascular
Technology Platform
Integrated small molecule platform from discovery to commercialization, with a focus on kinase inhibitors and cardiovascular agents.
Opportunities
Further lifecycle management and label expansion for its flagship innovative drug, anlotinib, into new cancer types and combinations.
Risk Factors
Over-reliance on a single innovative product and potential pricing pressures from the National Reimbursement Drug List (NRDL) negotiations.
Competitive Landscape
A established competitor in oncology and cardiovascular generics, now proving its innovative capabilities with a marketed novel oncology drug.